Albert Einstein made some arithmetic errors and Bob Dylan hit a few off notes. But they were still geniuses.
American companies are spending more on research and development than a year ago, providing a welcome bright spot in the overall troublesome pace of business investment in the U.S. economy. And the permanence of the federal R&D tax credit since 2015 likely has played a significant role in this trend.
It’s not easy being a pharma CEO. The industry is currently taking a PR beating for raising the prices of its drugs, and not just for new medicines, but also ones that have been in the market for decades. But pharma CEOs counter that it’s increasingly tough to cover R&D expenses, though they are finding other ways to mitigate costs, including slashing other types of expenses and buying competitors.
The pursuit of new drugs is just one way to navigate the “innovate or exit” pharma world.
Manufacturers are constantly looking at new technologies to improve processes, cut costs and expand the breadth and depth of products they provide to customers. But how do you decide on the best way to get access to the needed technology?
Today's tough economy demands more intense scrutiny of investments in innovation. Innovation is no longer sufficient in itself, but rather there is a new desire for metrics with which to measure success. But can you really measure ROI based on corporate investment?
BASIC RESEARCH, NOW AT RISK, NEEDS MAJOR ATTENTION.
The U.S. must invest more in R&D and universities to retain its best and brightest.
Corporate VC arms fund smaller companies with big ideas.